Kamada (KMDA) to Release Earnings on Wednesday

Kamada (NASDAQ:KMDA) is scheduled to announce its earnings results before the market opens on Wednesday, November 13th. Analysts expect the company to announce earnings of $0.07 per share for the quarter. Kamada has set its FY 2024 guidance at EPS.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.02. Kamada had a return on equity of 6.15% and a net margin of 9.75%. The firm had revenue of $42.47 million for the quarter, compared to the consensus estimate of $39.70 million. On average, analysts expect Kamada to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Kamada Price Performance

Shares of NASDAQ KMDA opened at $5.99 on Thursday. The company has a market capitalization of $344.31 million, a P/E ratio of 22.19 and a beta of 1.05. Kamada has a one year low of $4.58 and a one year high of $6.53. The business’s 50-day moving average price is $5.42 and its two-hundred day moving average price is $5.43.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Kamada in a research note on Thursday, August 15th. StockNews.com lowered shares of Kamada from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 27th.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.